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Deferoxaminemesylate (DFO) is themost commonly used iron-chelating agent to treat transfusion-related hemosiderosis. Despite
the clear advantages for the use of DFO, numerous DFO-related systemic toxicities have been reported in the literature, as well as
sight-threatening ocular toxicity involving the retinal pigment epithelium (RPE). &e damage to the RPE can lead to visual 'eld
defects, color-vision defects, abnormal electrophysiological tests, and permanent visual deterioration.&e purpose of this review
is to provide an updated summary of the ocular 'ndings, including both functional and structural abnormalities, in DFO-treated
patients. In particular, we pay particular attention to analyzing results of multimodal technologies for retinal imaging, which help
ophthalmologists in the early diagnosis and correct management of DFO retinopathy. Fundus auto(uorescence, for example, is not
only useful for screening patients at high-risk of DFO retinopathy, but is also a prerequisite for identify speci'c high-risk patterns
of RPE changes that are relevant for the prognosis of the disease. In addition, optical coherence tomography may have a clinical
usefulness in detecting extent and location of di)erent retinal changes in DFO retinopathy. Finally, this review wants to underline
the need for universally approved guidelines for screening and followup of this particular disease.
1. Introduction
Deferoxamine mesylate (DFO) is the most used iron-
chelating drug to treat hemosiderosis secondary to transfu-
sions. Deferoxamine mesylate is most commonly adminis-
tered as a slow subcutaneous infusion but can also be given
intramuscularly or, less commonly, intravenously [1]. Long-
term treatment with blood transfusions e)ectively prevents
various complications of sickle cell anemia and can sustain
patients with chronic congenital and acquired refractory
anemia, including beta-thalassemia syndromes, myelodys-
plastic syndromes, myelo'brosis, aplastic anemia, and other
disorders [1]. &e use of iron-chelating agents is crucial for
the management of such diseases. Since the human body
has no physiologic mechanisms to discard excess iron [2],
the frequent blood transfusions required in these conditions
inevitably produce iron overload. If not treated, chronic iron
overload can result in multiple organ toxicities including
potentially fatal cardiac toxicity, hepatic 'brosis or cirrhosis,
impaired growth, failure of sexual maturation, and diabetes
[3]. In patients with thalassemia who undergo transfusion
from infancy, iron-induced liver disease and endocrine dis-
orders develop during childhood and are almost inexorably
followed by death from iron-induced cardiomyopathy in
adolescence [1]. Deferoxamine mesylate has also been used
for the treatment of acute iron intoxication and as a screening
test for increased aluminum body stores in chronic renal
failure [4, 5]. Deferoxamine mesylate has high a+nity for
ferric iron, thus removing iron from hemosiderin, ferritin,
and transferrin [6].
2. Complications of Deferoxamine
Mesylate Therapy
2.1. Side E)ects. Despite the clear advantages for the use
of DFO, numerous signi'cant drug-related toxicities have
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been reported in the literature. Systemic toxicities included
cardiovascular, respiratory, gastrointestinal, cutaneous, and
nervous systems [1], in addition to the propensity for bone
dysplasia [7] and high-frequency sensorineuronal hearing
loss [8–10]. Furthermore, DFO therapy may induce ocu-
lar toxicity consisting of retinal pigment epithelium (RPE)
changes, visual loss, and impaired night vision [6, 11]. As
a result, the damage to the RPE can lead to visual 'eld
defects, decreased visual acuity, color-vision defects, and
decreased responses during electroretinogram (ERG) and
electrooculogram (EOG) [11–13]. Since the 1980s, several case
reports and small case series have been reported con'rming
these 'ndings, which may develop not only a0er high-
dose intravenous but also a0er subcutaneous administration
(Table 1) [6, 9–30]. Varying conclusions have been reported
regarding reversibility of DFO toxicity [26]; while usually
visual de'cits recover a0er cessation of the medication [15,
31], some authors reported permanent visual deterioration
[13] or even progression of the retinopathy even a0er DFO
discontinuation [29, 32].
2.2. Mechanism of Toxicity. &e mechanism of DFO toxicity
has been extensively studied; however, it is still not well
understood. Rahi et al. were the 'rst to perform a histologic
and ultrastructure examination of an eye diagnosed with
DFO retinopathy [16]. &ey reported abnormalities that
resembled apoptotic changes of the RPE. &ese changes
included patchy depigmentation in the equatorial as well
as the posterior fundus, swelling and calci'cation of mito-
chondria, disorganization of the plasma membrane, loss of
microvilli from the apical surface, and vacuolation of the
cytoplasm. RPE cells appeared enlarged and projected into
the subretinal space, which sometimes showed detached and
rounded RPE cells containing typical melanin accumulation.
&ickening of Bruchmembrane overlying the RPE was noted
as well.
It is also known that administration of DFO results in
high fecal iron, copper, and zinc excretion due to the drug’s
chelation properties [33]. De Virgiliis et al. hypothesized
that DFO retinopathy may be related to either serum or
intracellular zinc and copper de'ciencies [33]. Indeed, zinc
or zinc compounds are known to enhance the antioxidative
capability of RPE cells [34, 35]. Pall et al. hypothesized that
DFO retinopathy may occur in situations where the dose of
DFO is too high compared to the stores of iron present [36].
In these situations, the excess DFO could bind copper and
result in copper-induced autooxidative damage.
More recently, Klettner et al. examined the direct toxic
e)ect ofDFOon cultured primaryRPE cells [37].&ese inves-
tigators were the 'rst to clarify in vitro that the toxic e)ect of
DFO to the RPE is direct and not secondary to trace element
depletion. In addition, they showed that the cell death was
mediated by the activation of p38 mitogen-activated protein
kinases. &ese protein kinases were previously shown to
be important for the execution of programmed cell death
a0er toxic stimuli [26]. Finally, the investigators indicated a
general involvement of p38 in stress-induced cell death in
RPE cells, since p38 is also involved in oxidative stress.
2.3. Incidence. &ere are di)erent estimates of the incidence
of retinal toxicity due to DFO. Olivieri et al. reported that
5.6% of patients receiving DFO therapy had RPE changes [9].
In a series of 52 regularly transfused patients who received
DFO by subcutaneous or intravenous infusion, Cohen et al.
found that only two patients had abnormal visual screening
tests; one of them was symptomatic and one was not [10].
Chen et al. reported on a series of 30 transfusion-dependent
patients receiving DFO in a dose of 40 to 50mg/kg subcu-
taneously overnight for 8 to 10 hours by pump, 4 to 7 days
per week, and detected no visual abnormality [8]. In another
series of 84 children with transfusional hemochromatosis,
drug-related ocular toxicity was found only in one patient
(1.2%) [26]. Finally, our group has recently reported on a large
series of 197 consecutive adult patients with beta-thalassemia
syndromes receiving chronic treatment with DFO and found
abnormal fundus auto(uorescence (FAF) which is not related
to other diseases in 9% of the patients [29].
2.4. Risk Factors. A clear relationship between drug dosage
and development of DFO retinopathy could not be identi'ed
in most case series [6, 14]. Previously cited risk factors for
visual loss in DFO retinopathy included blood-retinal barrier
breakdown associated with diabetes [14] and rheumatoid
arthritis [15], renal failure [13], andmetabolic encephalopathy
[15]. It is believed that blood-retinal breakdown, which can
be due to iron overload-induced diabetes or to the drug
itself, may increase DFO levels in the RPE and retina, thus
intensifying the local toxic e)ects of the drug [6]. It has
also been suggested that older age and longer duration of
DFO treatmentmay be associated withmore advanced forms
of retinopathy in patients with beta-thalassemia syndromes
[32, 38].
3. Clinical Presentation
Previously reported ocular 'ndings of DFO toxicity include
cataract, optic neuropathy, optic atrophy, and macular or
equatorial pigmentary degeneration [6, 9, 10, 12, 15, 33]. On
fundus examination, the acute stage of DFO retinopathy is
characterized by retinal opaci'cation or loss of transparency,
aswell as EOGandERGattenuation [6].&is stage is followed
by macular and/or equatorial RPE pigmentary mottling,
which persists even a0er functional recovery. Multiple case
reports have described characteristic fundus lesions of DFO
retinopathy seen by ophthalmoscopy and fundus photogra-
phy; these lesions included pigmentary retinopathy, bull’s eye
maculopathy, and vitelliform maculopathy [15, 19, 21, 25, 27].
However, the use of high-resolution imaging technologies
has demonstrated that DFO retinopathy may present oph-
thalmoscopically with a variety of RPE degenerative patterns
resembling pattern dystrophies or may present with only
minimal changes in the macula that can be easily missed
by indirect ophthalmoscopy [29]. Multimodal imaging using
confocal laser scanning ophthalmoscopy (cSLO) was shown
to be extremely useful in detecting early RPE changes related
to DFO retinopathy, as well as in analyzing longitudinal
modi'cations of the disease.
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4. Tests for Functional Abnormalities
4.1. Electrophysiology. Electrophysiological tests have been
widely used to establish the diagnosis of DFO retinopathy.
&ey are essential for gathering information on the location
and extent of retinal dysfunction in patients with this pathol-
ogy.&e degree of functional loss in DFO retinopathy can be
assessed by using ERG or also EOG. Electrophysiology is a
valuable tool that is usually con'rmatory for the diagnosis,
and sometimes may also indicate more widespread dysfunc-
tion than may be implied by funduscopy alone. Electrophysi-
ology performed in rats given intravenous DFO showed early
dose-related suppression of b-wave amplitude [39, 40] that
in some cases were reversible [41]. Arden et al. studied 43
patients with thalassemia major and intermedia requiring
regular blood transfusions without any ocular symptoms.
&ey found that while EOG and ERG results where only
slightly and insigni'cantly lower than average, pattern ERG
abnormalities were much more pronounced [14]. Multifocal
ERG was found to be helpful as well in demonstrating areas
of decreasing function over time inDFOmaculopathy [23]. A
longitudinal ERG study in 11 beta-thalassemia major patients
receiving DFO suggested scotopic dysfunction, most likely
related to iron toxicity [42]. Lakhanpal et al. used electrophys-
iological tests to study eight patients who developed ocular
toxicity while undergoing DFO therapy for transfusional
haemosiderosis and suggested toxicity at the level of the
RPE and photoreceptors [12]. Haimovici et al. performed
electrophysiological tests on 16 patients with visual loss and
macular pigmentary changes related to DFO retinopathy.
&ey found reduced ERGamplitudes and reduced EOG light-
peak to dark-trough ratios indicating retinal and RPE injury
[6]. Electrophysiological results may also normalize a0er
splenectomy and cessation of DFO therapy [22].
4.2. Visual Field. Several case reports and case series reported
on visual 'eld alterations in patients undergoing long-term
DFO treatment. &e most common alterations were a gen-
eralized constriction of the visual 'eld [14, 28] or central-
paracentral scotomata [17, 25, 27]. Rahi et al. reported a case
that presented with both central scotoma and constriction
of the peripheral 'eld in each eye [16]. &ese abnormalities
resolved a0er withdrawal of high-dose therapy.
4.3.Microperimetry. Todate,microperimetric results inDFO
retinopathy have not been reported in the literature.However,
microperimetry can be a useful tool to study the impact of
macular RPE changes on visual function in this disease.&e
latest models of microperimeters incorporate a color fundus
camera for image registration and an autotracking system
to facilitate the accurate measurement of retinal sensitivity
within the central visual 'eld, even in patients with unstable
or extrafoveal 'xation. &is allows detection of absolute
scotomata, relative scotomata, or abnormally reduced retinal
sensitivity in patients with macular pathologies. Examples
of microperimetric results in eyes with DFO retinopathy are
shown in Figure 1.
5. Tests for Structural Abnormalities
5.1. Fluorescein Angiography. In the past, (uorescein angiog-
raphy (FA) has been widely used to diagnose DFO retinopa-
thy [6, 17, 20, 21, 23, 27, 28]. In the earliest stages, when
ophthalmoscopy shows loss of retinal transparency only, FA
shows patchy blocked fundus (uorescence followed by late
staining (Figure 2). When pigment mottling develops, FA
shows mottled (uorescence in the early-phase angiogram
with late hyper(uorescence [6]. However, these FA 'ndings
are not pathognomonic of DFO retinopathy. With the advent
of noninvasive high-resolution imaging technologies such as
the cSLO, FA is now only rarely required for the diagnosis of
patients with DFO retinopathy.
5.2. Fundus Auto*uorescence on Confocal Scanning Laser
Ophthalmoscopy. To date, FAF imaging using cSLO seems
to be the most e)ective clinical adjunct for the diagnosis
and evaluation of patients with DFO retinopathy [29]. &e
FAF signal generally provides indirect information on the
level of metabolic activity of the RPE, since it represents an
index of lipofuscin accumulation [43]. Fundus auto(uores-
cence appearance of a normal fundus is characterized by
a homogeneous background auto(uorescence arising from
the RPE, with a gradual decrease in macular FAF intensity
towards the foveola that results from the masking e)ect of
yellow macular pigment. &is suggests that, in vivo, FAF
imaging may represent a suitable noninvasive diagnostic tool
to detect early RPE abnormalities in various retinal disorders,
including drug-related retinal toxicity [44]. Indeed, it has
been shown that FAF imaging is superior to ophthalmoscopy
in detection of early characteristic RPE abnormalities in
patients at risk of DFO retinopathy, as well as in monitoring
the disease progression over time [29].
In 2012, our group described a variety of phenotypic
patterns of abnormal FAF in thalassemic patients who needed
long-term DFO treatment with the use of a cSLO device
[29]. &e topographic FAF alterations were classi'ed into
four di)erent patterns using a slightly modi'ed classi'cation
for age-related macular degeneration published by the FAM
Study group [45]. &e characteristics of each pattern are
described below.
(1) Minimal Change Pattern (Figure 3). Eyes with only mini-
mal variations from the normal FAF appearance, with irreg-
ularly increased or decreased background FAF, are included
in this group. Increased FAF signal, which may result from
mottling of the RPE, is characterized by relatively small spots
of less than 100 microns in diameter within the macula.&e
spots have well-de'ned borders and in some cases corre-
spond to visible alterations on color fundus photographs,
such as focal hyperpigmentation.
(2) Focal Pattern (Figure 4). &is pattern is de'ned by the
presence of at least one medium-sized spot, more than 100
microns but less than 200 microns in diameter, of markedly
increased FAF that is much brighter than the surrounding
background FAF. &e borders appear well-de'ned, with no
gradual decrease of FAF observed between the background
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(a) (b)
Figure 1: Microperimetric results in two eyes with DFO retinopathy. Absolute scotomata are present in macular areas of RPE atrophy as seen
on fundus photography. Relative scotomata or reduced retinal sensitivity are present in the adjacent areas where RPE changes may or may
not be visible.
(a) (b)
Figure 2: Early (a) and late phase (b) (uorescein angiography in an eye with DFO retinopathy.&e angiogram showed patchy blocked fundus
(uorescence in early phase in the macula, followed by late staining.
and the areawith focally increased FAF.On color fundus pho-
tographs these spots may correspond to visible alterations,
such as focal hyperpigmented areas.
(3) Patchy Pattern (Figure 5). &is pattern is characterized
by the presence of at least one large area, more than 200
microns in diameter, of markedly increased FAF. &ese
areas are brighter than the surrounding background FAF,
usually with well-de'ned borders. Nevertheless, coalescence
of these areas usually occurs, resembling a pattern dystro-
phy. &e corresponding abnormalities are visible on color
fundus photographs and include both hyperpigmentation
and hypopigmentation. To note, the a)ected area can o0en
appear larger in FAF imaging than that expected from the
color fundus photographs and sometimes it includes di)erent
intensities of hyperauto(uorescence.
(4) Speckled Pattern (Figure 6). &e speckled pattern is
de'ned by the simultaneous presence of a variety of FAF
changes that extend beyond the macula. Typically, these
abnormalities include multiple small areas of irregularly
increased and decreased FAF. On color fundus photographs,
these abnormalities sometimes correspond to visible alter-
ations such as focal hyperpigmentation and hypopigmenta-
tion.&e pathologic areas seem to be fewer and smaller than
the corresponding color fundus photographs.
As reported by our group, the detected FAF alterations in
DFO retinopathywere always bilateral but asymmetrical [29].
&e most frequent pattern was the minimal change pattern
(56%), followed by the focal pattern (17%), the patchy pattern
(16%), and the speckled pattern (11%). No association was
found between pattern type and duration of DFO treatment.
Areas of increased FAF signal indicated di)use accumulation
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(a) (b)
Figure 3: Color photo (a) and FAF image (b) of a minimal change pattern of DFO retinopathy.
(a) (b)
Figure 4: Color photo (a) and FAF image (b) of a focal pattern of DFO retinopathy.
(a) (b)
Figure 5: Color photo (a) and FAF image (b) of a patchy pattern of DFO retinopathy.
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(a) (b)
Figure 6: Color photo (a) and FAF image (b) of a speckled pattern of DFO retinopathy.
(a) (b)
(c) (d)
Figure 7: Serial fundus auto(uorescence (FAF) images of a patient with patchy pattern during a 5-year follow-up. (a) Presence of a patchy area
with mildly increased FAF in the inferior macula at baseline examination, involving the fovea. (b) At year 2, the patchy area showed a much
greater and uniform increased FAF signal compared to the previous visit. (c) At year 4, part of the patchy area of increased FAF signal started
disappearing, and areas of retinal pigment epithelium atrophy started developing. (d) At year 5, most parts of the patchy area of increased
FAF signal shrunk and disappeared, leading to frank retinal pigment epithelium atrophy in the macula.
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(a) (b)
(c)
Figure 8: Serial fundus auto(uorescence (FAF) images of a patient with speckled pattern during a 3-year follow-up. (a) At baseline
examination, multiple granular spots of increased FAF were clearly detected in the macula and also beyond the vascular arcades. In the
perifoveal area the spots were partially con(uent. (b) A0er 1 year, the perifoveal spots began to progressively disappear and initial RPE
atrophy occurred. (c) At year 3, further enlargement of the RPE atrophy in the macula as well as further reduction of the perimacular spots
of increased FAF signal were clearly detected.
of auto(uorescent (uorophores within a thickened RPE-
Bruch membrane complex or also focal accumulation of
auto(uorescent outer segment-derived retinoid products in
the subretinal space. &e di)erent intensities of hyperaut-
o(uorescence could be related to the presence of various
materials within di)erent retinal locations.
Besides being extremely helpful for detecting early RPE
changes, FAF has been shown to be very useful in evaluating
the clinical course of DFO retinopathy as well. To date, the
longest average follow-up of cases of DFO retinopathy using
multimodal imaging including FAF is 20 months (range:
10 to 45 months) [32]. In cases of minimal changes in the
macula, a slight enlargement of the a)ected areas developed
over the course of the years if DFO was not discontinued.
Limited FAF changes were detected in eyes with focal
pattern, independently from the ongoing or discontinued
DFO treatment. In cases of patchy pattern (Figure 7) or
speckled pattern (Figure 8), follow-up examinations revealed
progressive development of RPE atrophy in the previously
a)ected hyperauto(uorescent areas. In addition, RPE atrophy
progressively enlarged during the ensuing visits, leading to
irreversible vision loss. Notably, none of the patients with
patchy pattern could discontinue DFO treatment due to their
precarious systemic conditions [29, 32].
Patients with minimal changes in the macula were found
to be younger than patientswith the other patterns [32]. It was
therefore hypothesized that minimal changes related to DFO
retinopathy may progress into other patterns with increasing
age of the patients. However, a longitudinal study with longer
follow-up duration is necessary to detect a signi'cant disease
progression from one pattern to another.
5.3. Spectral Domain Optical Coherence Tomography. Spec-
tral domain optical coherence tomography (SD-OCT) may
have a clinical usefulness in detecting extent and location
of the di)erent retinal degenerations in DFO retinopathy
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Figure 9: Serial color photos and OCT scans of a patient with speckled pattern during a 3-year follow-up. (a) At baseline examination,
pigmented material was visible in the fovea, with small yellow (ecks extending beyond the vascular arcades. On OCT scan, granular
hyperre(ective deposits were detected in the subretinal space, extending into the outer plexiform layer and interrupting the overlying external
limiting membrane. (b) A0er 1 year, initial RPE atrophy was visible around the fovea, with disruption of the outer retinal layers on OCT scan.
(c) At year 3, frank RPE atrophy developed in the macula; OCT scan showed atrophy of the outer retinal layers and RPE, as well as thinning
of the inner retina.
(a) (b)
(c) (d)
Figure 10: Serial color photos andOCT scans of a patientwith patchy pattern during a 5-year follow-up. (a)At baseline examination, yellowish
vitelliform-like material was visible on fundus photo; OCT scan showed that the material was homogeneous, mildly hyperre(ective, and
localized in the subretinal space above the RPE. It was associated with a di)usely thickened inner segment/outer segment junction and
intact external limiting membrane. (b) A0er 1 year, the vitelliform material started resorbing inferonasally to the fovea; on OCT scan, the
subretinal material was no more homogeneous. (c) At year 3, the vitelliform material shrunk, and initial RPE and photoreceptors atrophy
were appreciated perifoveally. (d) At year 5, the vitelliform material was completely resorbed; OCT scan showed absence of external limiting
membrane, marked thinning of the outer nuclear layer, and frank RPE and photoreceptors atrophy in the macula.
[30, 32]. Some SD-OCT devices can also couple OCT scan
and bidimensional cSLO image to simultaneously colocal-
ize posterior structures with high accuracy [46]. In early
stage of the disease, SD-OCT usually shows only focal
thickenings or bumps of the RPE, resembling basal laminar
drusen. As the disease progresses, the coalescence of these
bumps of pigmented material appears on SD-OCT as thick
and hyperre(ective dome-shaped lesions that disrupts the
architecture of the overlying outer retinal layers. As the
pigmented material reabsorbs, RPE becomes progressively
thinner (Figure 9). Sometimes vitelliform-likematerial could
develop in the subretinal space above the RPE (Figure 10),
associated with a di)usely thickened inner segment/outer
segment junction. In advanced stages of DFO retinopathy,
frank RPE and photoreceptors atrophy may develop in the
macula, as well as migration of hyperre(ective subretinal
deposits towards the outer plexiform layer interrupting the
overlying external limiting membrane [32].
6. Management
Currently, there are no approved guidelines for the screening
and follow-up of DFO retinopathy in patients requiring
regular blood transfusions. Also, there is no treatment avail-
able for patients with DFO retinopathy other than drug
discontinuation or dose reduction. To minimize risks of
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DFO retinopathy, it has been suggested to not exceed doses
of 50mg/kg of body weight in patients with iron overload
and to decrease the dose as the hepatic iron concentration
approaches normal levels [1]. Although treatment with DFO
may reduce endocrine complications of iron overload, such
as a delay of puberty, the chelator itself can interfere with
growth [47], apparently as a result of skeletal dysplasia
[48]. To minimize this e)ect, the dose of DFO in children
should not exceed 25 to 30mg/kg [49]. Since ocular changes
related to DFO toxicity are potentially sight-threatening, we
believe that regular ocular checkups are essential for patients
undergoing treatment. &e presence of minimal changes in
the macula can be followed every 6 months, but patients
with certain toxicity such as bilateral pattern dystrophy-like
changes should stop the drug immediately unless the risks
of their underlying disease outweigh the risks of permanent
and possibly progressive visual loss. Even a0er cessation of
the drug, we recommend patients to return for reexamination
every 3months.
New iron-chelating therapies (deferasirox and deferi-
prone) are now available in the market, but their long-term
ocular safety has not been comprehensively investigated.
Moreover, the data considering side e)ects of deferiprone
and deferasirox are controversial [50, 51], yet there are studies
in which deferiprone seems to display fewer side e)ects than
DFO [52]. In particular, deferasirox could cause potentially
fatal renal and hepatic impairment or failure as well as
gastrointestinal hemorrhage [1]. &ese adverse e)ects were
reported to occur more frequently in older patients and in
patients with high-risk myelodysplastic syndromes, throm-
bocytopenia, or underlying renal or hepatic impairment.
Deferiprone could cause diarrhea and gastrointestinal e)ects,
arthropathy, increased levels of serum liver enzymes, and
progression of hepatic 'brosis associated with an increase in
iron overload or hepatitis C.&e most serious adverse e)ects
are agranulocytosis and neutropenia; weekly monitoring of
the neutrophil count is recommended [1].
7. Conclusion
Deferoxamine mesylate is the most important drug for the
treatment of hemosiderosis secondary to long-term treat-
ment with blood transfusions. Many di)erent ocular toxici-
ties have been reported in the literature, with the most seri-
ous being sight-threatening retinopathy. Currently, no “gold
standard” exists for identi'cation of the ocular toxicity prior
to its development.&is has led to the importance of repeated
ophthalmologic examinations for screening patients. With
the development of high-resolution noninvasive imaging
technologies, we believe that FAF can be used as a rapid
and reliable way to evaluate DFO retinopathy. Fundus aut-
o(uorescence imaging on a cSLO device not only is useful
for screening patients at high-risk of the disease, but it also
allows longitudinal evaluation of eyes with DFO retinopathy.
&ese changes are more widespread on FAF imaging than
expected from fundoscopy, and DFO retinopathy may also
present with di)erent FAF patterns that are relevant for the
prognosis of the disease. Fundus auto(uorescence imaging is
a prerequisite for identifying speci'c high-risk characteristics
(such as patchy or speckled patterns) that may be helpful in
the decision to discontinue or switch iron-chelating therapy
to prevent disease progression and irreversible visual loss
due to RPE atrophy. In addition to FAF imaging, SD-
OCT may have a clinical usefulness in detecting extent and
location of di)erent retinal changes in DFO retinopathy.
Further, longitudinal, multicenter studies with longer follow-
up and larger population may clarify any relationship with
the onset of a particular FAF pattern, any progression from
one pattern to another, and whether or not retinal alterations
have functional (e.g., localized scotomas) and/or prognostic
(e.g., on the development of choroidal neovascularization)
consequences.
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